Preclinical Studies of Posttraumatic Headache and the Potential Therapeutics

卷:12

Review

关键词: TRAUMATIC BRAIN-INJURY;    GENE-RELATED PEPTIDE;    ROSTRAL VENTROMEDIAL MEDULLA;    CANNABINOID-INDUCED ANTINOCICEPTION;    CORTICAL SPREADING DEPRESSION;    IMPROVES FUNCTIONAL RECOVERY;    SATELLITE GLIAL-CELLS;    CHRONIC MIGRAINE;    TRIGEMINOVASCULAR SYSTEM;    MOUSE MODEL;   

DOI  :  10.3390/cells12010155

来源: SCIE

【 摘 要 】

Posttraumatic headache (PTH) attributed to traumatic brain injury (TBI) is a secondary headache developed within 7 days after head injury, and in a substantial number of patients PTH becomes chronic and lasts for more than 3 months. Current medications are almost entirely relied on the treatment of primary headache such as migraine, due to its migraine-like phenotype and the limited understanding on the PTH pathogenic mechanisms. To this end, increasing preclinical studies have been conducted in the last decade. We focus in this review on the trigeminovascular system from the animal studies since it provides the primary nociceptive sensory afferents innervating the head and face region, and the pathological changes in the trigeminal pathway are thought to play a key role in the development of PTH. In addition to the pathologies, PTH-like behaviors induced by TBI and further exacerbated by nitroglycerin, a general headache inducer through vasodilation are reviewed. We will overview the current pharmacotherapies including calcitonin gene-related peptide (CGRP) monoclonal antibody and sumatriptan in the PTH animal models. Given that modulation of the endocannabinoid (eCB) system has been well-documented in the treatment of migraine and TBI, the therapeutic potential of eCB in PTH will also be discussed.